Court Restrains Orziva Healthcare from Using Deceptively Similar Marks to Protect Emcure's OROFER Brand
In a significant ruling, the Delhi High Court has granted an interim injunction in favor of Emcure Pharmaceuticals Limited, restraining Orziva Healthcare Private Limited from using marks that are deceptively similar to Emcure's registered trademarks, particularly OROFER. The decision, delivered by Ms. Jyoti Singh, J., highlights the court's commitment to safeguarding intellectual property rights and preventing consumer confusion in the pharmaceutical industry.
The case arose when Emcure Pharmaceuticals, a leading global pharmaceutical company, alleged that Orziva Healthcare had adopted the mark ORZIFER-XT, which closely resembles Emcure's well-known OROFER trademark. Emcure argued that this similarity was likely to cause confusion among consumers, especially given the identical nature of the products involved, which are used for treating anemia, a condition particularly concerning for pregnant women.
The court, after reviewing the documents and hearing Emcure's counsel, found that the plaintiff had established a prima facie case for trademark infringement and passing off. Emcure demonstrated that it is the registered proprietor of the OROFER trademark and its variants, which have been in continuous use since 1996 for gynecological products. The court noted that the impugned marks used by Orziva are visually, structurally, and phonetically similar to Emcure's trademarks, thereby violating Emcure's statutory rights to exclusive use.
Judge Jyoti Singh observed that the defendants' actions could cause irreparable harm to Emcure's goodwill and reputation, built over years of successful branding and consumer trust. The court emphasized the importance of protecting consumers from potential confusion arising from such deceptive similarities, especially when it involves products that are critical to health and safety.
In granting the interim injunction, the court applied the trinity principles for granting injunctions, which include the presence of a prima facie case, balance of convenience, and the likelihood of irreparable harm. The court restrained Orziva Healthcare and its associates from manufacturing, selling, or promoting products under the impugned marks ORZIFER-XT or any other marks deceptively similar to Emcure's trademarks until the next hearing date, scheduled for September 25, 2026.
This ruling underscores the judiciary's proactive stance in protecting intellectual property rights in India, particularly in the pharmaceutical sector, where consumer safety and brand reputation are paramount. The case highlights the challenges companies face in maintaining brand integrity and the legal recourse available to combat infringement and passing off.
Bottom line:-
Intellectual Property Law - Trademark infringement and passing off - Interim injunction granted to restrain Defendants from using marks deceptively similar to Plaintiff's registered trademarks.
Statutory provision(s): Trade Marks Act, 1999 Section 29, Civil Procedure Code, 1908 Order XXXIX Rule 1 and 2
